AMGN

#70
Amgen Inc
349.63 USD
-0.05%
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
349.33
350.60
Jahresspanne
261.43
391.29
Tagesänderung
-0.05%
Monatliche Änderung
-5.35%
6 month change
+19.00%
Jahresänderung
+19.04%
Vorheriger Schlusskurs
349.82
Eröffnung
350.24
Bid
Ask
Tief
349.33
High
350.60
Volumen
467
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Dividenden
Vierteljährlich Jährlich
  • Market Capitalization 188.47 B
  • Employee 32 K
  • Founded 1980
  • CEO Robert A. Bradway
  • Website www.amgen.com
  • Headquarter Delaware, United States
  • FIGI BBG000BBS2Y0
  • Industry Technology
Gesamtumsatz
Jahresüberschuss
Unverwässertes Ergebnis je Aktie (Unverwässertes EPS)
Gesamtverschuldung
Freier Cashflow
Zahlungsmittel und Zahlungsmitteläquivalente
Kurs-Gewinn-Verhältnis
23
Preis-Umsatz-Verhältnis
4.83
Dividende je Aktie
2.52
Dividendenrendite in %
2.95

Amgen Inc

Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics. The company's major products are Prolia and XGEVA for treatment of osteoporosis and bone diseases, Enbrel for treatment of autoimmune diseases, Repatha for treatment of hyperlipidemia, Otezla for treatment of psoriasis and psoriatic arthritis, Tepezza to treat Graves' ophthalmopathy, Evenity to treat osteoporosis, Kyprolis to treat cancer, Nplate to regulate platelet production, and Aranesp to stimulate erythropoiesis. Amgen has 17 clinical programs underway in Phase III, eight in Phase II, and 19 in Phase I. Its pipeline includes MariTide, an anti-obesity medication administered once per month by injection. The company receives approximately 80% of its revenues from sales to the three large U.S. drug wholesalers: McKesson Corporation, Cencora, and Cardinal Health. The company is ranked 134th on the Fortune 500 and 202nd on the Forbes Global 2000.

Nachrichten